Nucleus RadioPharma, Inc. announced that it will issue 10,547,047 series A preferred shares at issue price of $5.8879 per share for the gross proceeds of $62,099,958.0313 in funding on September 15, 2023. The shares are convertible and non-redeemable. The shares will be convertible into common shares at a price of $5.8879 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
76.49 USD | -0.65% | +0.20% | -1.07% |
10/06 | GE HealthCare Reports Changes in Key Segments | MT |
10/06 | GE Healthcare Technologies Inc. Announces Management Changes | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.07% | 34.92B | |
+7.77% | 218B | |
+10.16% | 189B | |
+26.21% | 151B | |
+32.78% | 113B | |
+1.98% | 64.02B | |
+14.48% | 52.6B | |
+2.92% | 49.85B | |
-6.60% | 37.89B | |
+23.08% | 31.1B |
- Stock Market
- Equities
- GEHC Stock
- News GE HealthCare Technologies Inc.
- Nucleus RadioPharma, Inc. announced that it expects to receive $62.099958 million in funding